Trial overview

A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia.

For precursor-B lineage ALL, the main aim is to determine if the addition of Rituximab to standard induction chemotherapy results in improved EFS.

For T lineage ALL, the main aim is to determine if the addition of nelarabine following standard induction therapy improves outcomes.

Inclusion criteria

  1. Subjects must be aged between 25 and 65 years old with acute lymphoblastic leukaemia.
  2. Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days is required and can be started prior to registration).
  3. Written informed consent.


Exclusion criteria

  1. Known HIV infection.
  2. Pregnant or lactating women.
  3. Blast transformation of CML.
  4. Mature B-cell leukaemia (i.e. Burkitt’s lymphoma t(8;14)(q24;q32) and variant  c-myc translocations e.g. t(2;8)(p12;q24), t(8;22)(q24;q11) ).

Contact details

Principal Investigator

Rod Johnson



Research Nurse

Amy Humphries

Tel 0113 2068984


Other trials currently active for Acute Lymphoblastic Leukaemia


United Kingdom National Randomised Trial For Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011



A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia


ukall 14 ukall